MedPath

A study to compare efficacy and safety of levocetrizine versus levocetrizine alongwith probiotic in allergic rhinitis patient

Phase 4
Conditions
Health Condition 1: J309- Allergic rhinitis, unspecified
Registration Number
CTRI/2023/11/059620
Lead Sponsor
Shujauddin
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Seasonal/Throughout year rhinitis

2. Patients with a symptom severity score of least 6 out of 15

3. Patients who were not on any anti-allergy preparations for at least 15 days

Exclusion Criteria

1. Patients below 18 years of age

2. Pregnant women

3. Allergic rhinitis with nasal polyps

4. Fungal rhinitis

5. Vasomotor rhinitis

6. Patients with history of asthma and non-allergic causes of rhinitis

7. Patients with rhinosinusitis other than allergic rhinitis

8. Patients with sino-nasal tumours

9. Recurrence/Post surgical rhinitis

10. Patients with co morbid condition (renal, hepatic, cardiac, endocrine)

11. Patient who will not come for follow-up visit

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate and compare the efficacy of Oral Levocetirizine versus Oral Levocetirizine and Oral Probiotics in patient with allergic rhinitis <br/ ><br>Outcome will be assessed by Change in the Total Nasal Symptom score throughout the study periodTimepoint: first day, 2nd week, 6th week, 12th week
Secondary Outcome Measures
NameTimeMethod
1. Safety profile of Oral Levocetirizine versus Oral Levocetirizine and Oral Probiotics in patient with allergic rhinitis. <br/ ><br> <br/ ><br>Timepoint: first day, 2nd week, 6th week 12th wee;Measure the Quality of Life in patients of allergic rhinitis on Oral Levocetirizine versus Oral Levocetirizine and Oral Probiotics by Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).Timepoint: first day, 2nd week, 6th week, 12th week
© Copyright 2025. All Rights Reserved by MedPath